View PDF Version - RePub - Erasmus Universiteit Rotterdam

Viral dynamics during tenofovir therapy 205
15. Ristig MB, Crippin J, Aberg JA et al. Tenofovir disoproxil fumarate therapy for chronic hepatitis
B in human immu nodeficiency virus/hepatitis B virus-coinfected individuals for whom
interferon-alpha and lamivudine therapy have failed. J Infect Dis 2002; 186(12): 1844–1847.
16. van Bommel F, Wunsche T, Schurmann D, Berg T. Ten ofovir treatment in patients with
lamivudine-resistant hepatitis B mutants strongly affects viral replication. Hepa tology 2002;
36(2): 507–508.
17. van Bommel F, Schernick A, Hopf U, Berg T. Tenofovir disoproxil fumarate exhibits strong
antiviral effect in a pa tient with lamivudine-resistant severe hepatitis B reactiva tion. Gastroenterology
2003; 124(2): 586–587.
18. Neumann AU, Lam NP, Dahari H et al. Hepatitis C viral dynamics in vivo and the antiviral
efficacy of interferon-alpha therapy. Science 1998; 282(5386): 103–107.
19. Wolters LM, Hansen BE, Niesters HG, Zeuzem S, Schalm SW, de Man RA. Viral dynamics in
chronic hepatitis B pa tients during lamivudine therapy. Liver 2002; 22(2): 121– 126.
20. Pas SD, Fries E, de Man RA, Osterhaus AD, Niesters HG. Development of a quantitative
real-time detection assay for hepatitis B virus DNA and comparison with two commercial
assays. J Clin Microbiol 2000; 38(8): 2897–2901.
21. Heermann KH, Gerlich WH, Chudy M, Schaefer S, Thoms sen R. Quantitative detection of
hepatitis B virus DNA in two international reference plasma preparations. Eurohep Pathobiology
Group. J Clin Microbiol 1999; 37(1): 68–73.
22. Stuyver L, Van Geyt C, De Gendt S et al. Line probe assay for monitoring drug resistance
in hepatitis B virus-infected patients during antiviral therapy. J Clin Microbiol 2000; 38(2):
702–707.
23. Osterhaus AD, Vos MC, Balk AH et al. Transmission of hepatitis B virus among heart transplant
recipients during endomyocardial biopsy procedures. J Heart Lung Transplant 1998;
17(2): 158–166.
24. Tsiang M, Rooney JF, Toole JJ, Gibbs CS. Biphasic clearance kinetics of hepatitis B virus from
patients during adefovir dipivoxil therapy. Hepatology 1999; 29(6): 1863–1869.
25. Nowak MA, Bonhoeffer S, Hill AM, Boehme R, Thomas HC, McDade H. Viral dynamics in
hepatitis B virus infection. Proc Natl Acad Sci U S A 1996; 93(9): 4398–4402.
26. Neumann AU, Ronen T, Tsiang M et al. Predictive HBeAg loss by HBV DNA early kinetics
and HBV genotype during treatment of HBeAg+ chronic hepatitis B (CHB) patients with
adefovir dipivoxil (ADV) J Hepatol 2003; 38 (Suppl. 2): 26.
27 . Benhamou Y, Bochet M, Thibault V et al. Safety and efficacy B of adefovir dipivoxil in
patients co-infected with HIV-1 lamivudine-resistant hepatitis B virus: an open-label pilot
study. Lancet 2001; 358(9283): 718–723.
28. Wolters LM, Hansen BE, Niesters HG et al. The influence loss by HBV DNA early kinetics and
HBV genotype during of baseline characteristics on viral dynamic parameters treatment
of HBeAg+ chronic hepatitis B (CHB) patients in chronic hepatitis B patients treated with
lamivudine. with adefovir dipivoxil (ADV). J Hepatol 2002; 37(2): 253–258.